一、审议程序 江苏鱼跃医疗设备股份有限公司（以下简称"公司"或"本公司"）于 2025 年 10 月 24 日召开第六届董事会第十二次临时会议、第六届监事会第五次临时会 议，审议通过了关于《公司 2025 年前三季度利润分配方案》的议案，该议案尚 需提交公司股东大会审议通过。 二、公司 2025 年前三季度利润分配方案情况 证券代码：002223 证券简称：鱼跃医疗 公告编号：2025-037 江苏鱼跃医疗设备股份有限公司 关于公司 2025 年前三季度利润分配方案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 四、其他说明 1、本次利润分配方案需经股东大会审议通过后方可实施，存在不确定性， 敬请广大投资者理性投资，注意投资风险； 2、本次利润分配方案披露前，公司严格控制内幕信息知情人的范围，并对 相关内幕信息知情人履行了保密和严禁内幕交易的告知义务。 五、备查文件 1、第六届董事会第十二次临时会议决议； 根据公司 2025 年三季度财务报告（未经审计），公司 2025 年 1-9 月母公司 净利润为人民币 1,029,628,391.21 元，截至 ...

Core Viewpoint - The Biotech Index (970038) closed at 2259.94 points, down 0.06%, with a trading volume of 17.182 billion yuan and a turnover rate of 1.24% on October 23 [1] Group 1: Index Performance - The Biotech Index had 26 stocks rising and 22 stocks falling on the day, with Huace Testing leading the gainers at a 3.03% increase, while Jingxin Pharmaceutical led the decliners with a 4.17% drop [1] - The top ten constituent stocks of the Biotech Index include: - Mindray Medical (13.81% weight, latest price 221.80, market cap 268.92 billion yuan) [1] - Changchun High-tech (5.41% weight, latest price 117.65, market cap 47.994 billion yuan) [1] - Kanglong Chemical (4.66% weight, latest price 31.44, market cap 55.906 billion yuan) [1] - Others include Shishi Yushang, Biao Ge Pharmaceutical, and more, all within the biotech and related sectors [1] Group 2: Capital Flow - The Biotech Index constituents experienced a net outflow of 502 million yuan from main funds, while retail investors saw a net inflow of 354 million yuan [3] - Detailed capital flow for key stocks includes: - Deep Technology: Main fund net inflow of 82.5949 million yuan, retail net inflow of 21.4 million yuan [3] - Mindray Medical: Main fund net inflow of 66.9479 million yuan, retail net outflow of 3.6088 million yuan [3] - Other stocks like Muyuan Foods and Kanglong Chemical also showed varying levels of net inflow and outflow from different investor categories [3]

Core Insights - Jiangsu enterprises are leveraging "innovation + green" as dual engines for high-quality development, showcasing the integration of traditional industries with emerging technologies [1][9] Group 1: Technological Innovation - Yuyue Medical has introduced the Anytime5 continuous glucose monitoring system, which collects data every three minutes and syncs with mobile devices, enhancing health management through AI and big data integration [3] - Hengshen Co., a leader in the carbon fiber industry, is expanding its production capacity with a 1.53 billion yuan investment in a new high-performance carbon fiber production base, aiming for a 20,000 tons/year output [3] - Ddeng Group, recognized as a national manufacturing "single champion," has developed a low-temperature sodium-ion battery in collaboration with Tsinghua University, achieving significant breakthroughs in energy storage technology [4] Group 2: Green Transformation - Jindong Paper has transformed into a national-level green factory, achieving 90% internal reuse of production wastewater and generating over 50 million kWh annually from its rooftop solar project, resulting in significant reductions in coal consumption and CO2 emissions [6] - Vick (Jiangsu) Environmental Equipment Co. integrates energy-saving concepts throughout its production process, utilizing rooftop solar panels and eco-friendly refrigerants in its air conditioning products [6] - Yangtze River Pharmaceutical Group's Jiangsu Longfeng Tang Traditional Chinese Medicine Co. employs a circular economy model, converting medicinal waste into biomass fuel and significantly reducing solid waste and CO2 emissions through its energy monitoring platform [7] Group 3: Resource Recycling - The National Energy Group's Taizhou Power Company has implemented a CO2 capture project with an annual capacity of 500,000 tons, utilizing the captured CO2 for chemical synthesis and oil recovery, promoting resource recycling [9] - The practices of these companies demonstrate that traditional industries can thrive through innovation, while emerging industries must also root themselves in innovative practices to expand into global markets [9]

证券日报网讯鱼跃医疗10月22日在互动平台回答投资者提问时表示，公司会合理统筹资金，使自有资金 更好地助力公司战略发展和业务布局，同时公司将继续坚定围绕主营业务，通过努力提高经营业绩，推 动公司长期稳步发展，为股东谋求长期、可持续的回报。如有应审议披露事项，公司将按照法规及时履 行审议程序与信息披露义务。 （文章来源：证券日报） ...

Core Viewpoint - Yuyue Medical has engaged in supplying high-altitude oxygen equipment for the construction of the Yarlung Zangbo River downstream hydropower station project, indicating a focus on expanding its service offerings in high-altitude medical oxygen solutions [2] Group 1: Company Activities - Yuyue Medical and its wholly-owned subsidiary, Tibet Yuyue Medical Investment Co., Ltd., have installed and supplied high-altitude oxygen products including central oxygen supply systems, desktop oxygen generators, portable oxygen generators, and portable oxygen respirators for the hydropower project [2] - The company aims to continue pursuing further cooperation opportunities related to high-altitude oxygen services for the hydropower project, ensuring ongoing health support for project builders [2] Group 2: Financial Impact - Currently, the orders obtained by the company are not expected to have a significant impact on overall performance, indicating a cautious outlook on immediate financial benefits from this engagement [2] - There remains a degree of uncertainty regarding future order acquisition, suggesting that investors should remain vigilant about potential risks associated with this venture [2]

Core Insights - The Biotech Economy Index (970038) closed at 2261.4 points, down 0.81%, with a trading volume of 16.635 billion yuan and a turnover rate of 1.19% [1] - Among the index constituents, 19 stocks rose while 30 stocks fell, with Meihao Medical leading the gainers at 6.53% and Prolo Pharma leading the decliners at 5.41% [1] Index Performance - The Biotech Economy Index experienced a decline of 0.81% on the reporting day [1] - The total market capitalization of the index constituents was significant, with major players like Mindray Medical valued at 266.98 billion yuan [1] Top Constituents - The top ten constituents of the Biotech Economy Index include: - Mindray Medical (13.81% weight, 220.20 yuan, -1.51% change, 2669.80 billion yuan market cap) [1] - Changchun High-tech (5.41% weight, 119.11 yuan, -0.97% change, 485.89 billion yuan market cap) [1] - Kanglong Chemical (4.66% weight, 30.96 yuan, +0.29% change, 550.53 billion yuan market cap) [1] - Other notable constituents include Taige Pharmaceutical, Muyuans, and Aimeike, all within the biotech and healthcare sectors [1] Capital Flow - The net outflow of main funds from the Biotech Economy Index constituents totaled 0.893 billion yuan, while retail investors saw a net inflow of 0.75 billion yuan [1] - Specific stocks like Kanglong Chemical and Meihao Medical experienced varying levels of net inflow and outflow from different investor categories [2]

10月17日-19日，第八届华佗杯·全国高等院校针灸推拿临床技能大赛（以下称"大赛"）圆满举办。会 上，鱼跃医疗（002223）旗下中医医疗器械品牌"华佗"与中国针灸学会正式签约，继续赞助未来十年共 五届大赛。 成果丰硕，华佗助力赛事再上新台阶 今年，来自全国多所高校的代表队同台竞技，展示扎实的理论知识与精湛的临床技艺。这已是华佗赞助 的第5届赛事，作为长期赛事合作伙伴，华佗不仅提供全程赞助支持，其"一次性使用无菌针灸针"更被 选为大赛官方唯一指定用针，以专业品质为赛事保驾护航。 对于此次合作的全面升级，华佗总经理支华良表示："现场见证选手们出色的专业素养与创新潜力，让 我们更加明确，华佗对行业的支持不应仅停留在赛事层面，而应深入人才培养的全过程。因此，我们决 定将合作模式从连续赞助，升级为未来十年的'生态共建'。"此后，华佗将围绕学术交流、临床实践、 国际合作等多个层面，与各界携手夯实针灸事业发展根基，共同推进行业实现高质量、可持续发展。 打造"针"文化符号，推动中医智慧走向世界 华佗董事长张金岩指出："长久以来，'华佗'二字始终与高品质针灸针紧密相连。未来，我们希望将手 中的'针'，从具体的医疗器械升华为 ...

Core Insights - The article highlights the transformation and development paths of Jiangsu Yuyue Medical Equipment Co., Ltd. in the context of the home medical device industry's shift towards digitalization and internationalization [1][2] Group 1: Technological Innovation and Smart Manufacturing - Yuyue Medical has a research and development investment intensity of approximately 8%, positioning itself as a representative enterprise in the industry [1] - The company focuses on "data-driven" smart manufacturing, implementing intelligent production scheduling and logistics optimization systems for flexible manufacturing [1] - Yuyue Medical's smart manufacturing factory was recognized as a national "smart manufacturing pilot demonstration factory" in 2021, making it one of the few national-level smart manufacturing pilot enterprises in the medical device sector [1] Group 2: Global Expansion Strategy - Yuyue Medical has established over 50 channel agents in regions such as Southeast Asia, the Middle East, North Africa, Latin America, Western Europe, and North America, enhancing its international brand influence [2] - The company is committed to localizing operations by employing both Chinese and local staff to manage local markets effectively [2] - Yuyue Medical aims to introduce mature overseas technologies to China, leveraging domestic R&D advantages to quickly iterate new products and expand product lines for re-export [2] - The company achieved global sales of 1.3 million units of desktop oxygen concentrators last year, maintaining its position as the industry leader in this segment [2]

Core Insights - The cervical traction device market in China is projected to grow from 1.414 billion yuan in 2016 to 4.746 billion yuan in 2024, with a compound annual growth rate (CAGR) of 16.34% [1][10] - The increasing prevalence of cervical spondylosis among younger populations, particularly those under 30, has created a substantial user base for cervical traction devices [7][10] - Non-invasive conservative treatment options, such as cervical traction devices, are becoming the preferred choice due to their safety and convenience [1][10] Industry Overview - Cervical spondylosis is a degenerative condition affecting the cervical spine, with over 200 million patients in China, where more than 40% are under 30 years old [7][10] - The treatment methods for cervical spondylosis include non-surgical and surgical options, with traction being a primary non-surgical method to alleviate symptoms [3][7] - The cervical traction device market is supported by advancements in medical technology, leading to the development of smart and home-use devices that lower usage barriers [1][10] Market Dynamics - The cervical traction device industry is influenced by government policies promoting home medical devices and improving industry standards, creating a favorable environment for market expansion [1][10] - The medical device industry in China is experiencing rapid growth, with the overall market size expected to increase from 370 billion yuan in 2016 to 1.13 trillion yuan in 2024, reflecting a CAGR of 14.98% [10] Competitive Landscape - The cervical traction device market features a diverse competitive landscape, with established medical device companies and emerging tech firms participating [11] - Key players in the market include Yuyue Medical, Kefu Medical, and other brands that leverage innovation and user experience to capture the younger demographic [11] - The competition is shifting from price-based to technology development, user experience, and brand credibility, driving the industry towards standardization and quality improvement [11] Development Trends - The industry is moving towards smart devices that integrate high-precision sensors and algorithms for personalized treatment [13][14] - There is a growing trend towards personalized solutions based on individual physiological characteristics and specific conditions [14] - The demand for portable devices is increasing, with innovations in lightweight materials and compact designs enhancing user convenience [15]

Core Insights - The National Medical Products Administration (NMPA) emphasizes the importance of medical device quality and safety for public health, highlighting the need for strict regulatory measures and innovation support in the industry [1] Group 1: Regulatory Focus - The NMPA plans to implement the "four strictest" requirements to enhance the quality management system and capabilities for medical devices [1] - There is a call for improved lifecycle quality supervision of medical devices, ensuring that companies fulfill their primary responsibilities in maintaining safety standards [1] Group 2: Innovation and Development - The NMPA aims to establish a supportive mechanism for the development of innovative medical devices, which includes ongoing reforms in the review and approval processes [1] - The focus is on promoting high-quality industrial innovation to better serve public health needs [1]